212-681-1575
May

12

Mesothelioma Patients to Benefit from Research Con...

Posted by

Label: Featured News


In December, MesotheliomaHelp.org reported the U.S. Food and Drug Administration approved Portrazza (necitumumab) for first-line treatment of people with metastatic squamous non-small cell lung cancer. Now, researchers confirm necitumumab is most Beneficial to Lung Cancer Patients expressing epidermal growth factor

Read Full Story

Want Specific topic updates?